Description

Moxiflox-Infuzia solution for infusions 400 mg/250 ml. 250 ml. vial

Ingredients

Moxifloxacin is the active ingredient in Moxiflox-Infuzia solution for infusions. It belongs to the fluoroquinolone class of antibiotics and is effective against a wide range of bacteria.

Dosage

The recommended dosage of Moxiflox-Infuzia solution for infusions is 400 mg administered intravenously over a period of 60 minutes. Dosage may vary depending on the condition being treated.

Indications

Moxiflox-Infuzia is indicated for the treatment of various bacterial infections, including respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections.

Contraindications

Do not use Moxiflox-Infuzia if you have a history of hypersensitivity to moxifloxacin or other quinolone antibiotics. It is also contraindicated in children, pregnant women, and nursing mothers.

Directions

Follow the instructions provided by your healthcare provider for the proper administration of Moxiflox-Infuzia solution for infusions. It is important to complete the full course of treatment as prescribed.

Scientific Evidence

Moxifloxacin has been extensively studied for its efficacy in treating various bacterial infections. Research published in the Journal of Antimicrobial Chemotherapy has shown that moxifloxacin is highly effective against both gram-positive and gram-negative bacteria.

Additional Information

It is important to note that Moxiflox-Infuzia solution for infusions should only be used under the supervision of a healthcare professional. Be sure to inform your doctor about any other medications you are taking to avoid potential drug interactions.

Pharmacological Effects: Moxifloxacin works by inhibiting the activity of bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for bacterial DNA replication and repair. This leads to the death of the bacteria and helps in the resolution of the infection.

Clinical Trials: Clinical trials have demonstrated the efficacy of Moxifloxacin in the treatment of various infections, with high rates of bacterial eradication and clinical improvement. A study published in the European Respiratory Journal showed that moxifloxacin was effective in treating community-acquired pneumonia.